Literature DB >> 24747948

Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics.

Julie A Vrana1, Jason D Theis1, Surendra Dasari2, Oana M Mereuta3, Angela Dispenzieri4, Steven R Zeldenrust4, Morie A Gertz4, Paul J Kurtin1, Karen L Grogg1, Ahmet Dogan5.   

Abstract

Examination of abdominal subcutaneous fat aspirates is a practical, sensitive and specific method for the diagnosis of systemic amyloidosis. Here we describe the development and implementation of a clinical assay using mass spectrometry-based proteomics to type amyloidosis in subcutaneous fat aspirates. First, we validated the assay comparing amyloid-positive (n=43) and -negative (n=26) subcutaneous fat aspirates. The assay classified amyloidosis with 88% sensitivity and 96% specificity. We then implemented the assay as a clinical test, and analyzed 366 amyloid-positive subcutaneous fat aspirates in a 4-year period as part of routine clinical care. The assay had a sensitivity of 90%, and diverse amyloid types, including immunoglobulin light chain (74%), transthyretin (13%), serum amyloid A (%1), gelsolin (1%), and lysozyme (1%), were identified. Using bioinformatics, we identified a universal amyloid proteome signature, which has high sensitivity and specificity for amyloidosis similar to that of Congo red staining. We curated proteome databases which included variant proteins associated with systemic amyloidosis, and identified clonotypic immunoglobulin variable gene usage in immunoglobulin light chain amyloidosis, and the variant peptides in hereditary transthyretin amyloidosis. In conclusion, mass spectrometry-based proteomic analysis of subcutaneous fat aspirates offers a powerful tool for the diagnosis and typing of systemic amyloidosis. The assay reveals the underlying pathogenesis by identifying variable gene usage in immunoglobulin light chains and the variant peptides in hereditary amyloidosis. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24747948      PMCID: PMC4077087          DOI: 10.3324/haematol.2013.102764

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  49 in total

1.  Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations.

Authors:  Joshua E Elias; Wilhelm Haas; Brendan K Faherty; Steven P Gygi
Journal:  Nat Methods       Date:  2005-09       Impact factor: 28.547

2.  Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis.

Authors:  Sanjeev Sethi; Jason D Theis; Nelson Leung; Angela Dispenzieri; Samih H Nasr; Mary E Fidler; Lynn D Cornell; Jeffrey D Gamez; Julie A Vrana; Ahmet Dogan
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

Review 3.  Amyloidosis: pathogenesis and new therapeutic options.

Authors:  Giampaolo Merlini; David C Seldin; Morie A Gertz
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

4.  A trinucleotide deletion in the transthyretin gene (delta V 122) in a kindred with familial amyloidotic polyneuropathy.

Authors:  T Uemichi; J J Liepnieks; M D Benson
Journal:  Neurology       Date:  1997-06       Impact factor: 9.910

5.  Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue.

Authors:  Christopher J Klein; Julie A Vrana; Jason D Theis; Peter J Dyck; P James B Dyck; Robert J Spinner; Michelle L Mauermann; H Robert Bergen; Steven R Zeldenrust; Ahmet Dogan
Journal:  Arch Neurol       Date:  2010-10-11

Review 6.  Primary systemic amyloidosis--a diagnostic primer.

Authors:  M A Gertz; R A Kyle
Journal:  Mayo Clin Proc       Date:  1989-12       Impact factor: 7.616

7.  A new transthyretin variant (Ser 24) associated with familial amyloid polyneuropathy.

Authors:  T Uemichi; M A Gertz; M D Benson
Journal:  J Med Genet       Date:  1995-04       Impact factor: 6.318

8.  Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.

Authors:  Francesca Lavatelli; David H Perlman; Brian Spencer; Tatiana Prokaeva; Mark E McComb; Roger Théberge; Lawreen H Connors; Vittorio Bellotti; David C Seldin; Giampaolo Merlini; Martha Skinner; Catherine E Costello
Journal:  Mol Cell Proteomics       Date:  2008-05-12       Impact factor: 5.911

9.  Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy.

Authors:  M M Reilly; D Adams; D R Booth; M B Davis; G Said; M Laubriat-Bianchin; M B Pepys; P K Thomas; A E Harding
Journal:  Brain       Date:  1995-08       Impact factor: 13.501

10.  Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis.

Authors:  Sanjeev Sethi; Julie A Vrana; Jason D Theis; Nelson Leung; Anjali Sethi; Samih H Nasr; Fernando C Fervenza; Lynn D Cornell; Mary E Fidler; Ahmet Dogan
Journal:  Kidney Int       Date:  2012-04-11       Impact factor: 10.612

View more
  38 in total

1.  Hereditary Lysozyme Amyloidosis Variant p.Leu102Ser Associates with Unique Phenotype.

Authors:  Samih H Nasr; Surendra Dasari; John R Mills; Jason D Theis; Michael T Zimmermann; Rafael Fonseca; Julie A Vrana; Steven J Lester; Brooke M McLaughlin; Robert Gillespie; W Edward Highsmith; John J Lee; Angela Dispenzieri; Paul J Kurtin
Journal:  J Am Soc Nephrol       Date:  2017-01-03       Impact factor: 10.121

2.  Abdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry.

Authors:  Kanji Miyazaki; Shigeo Kawai; Kenshi Suzuki
Journal:  Int J Hematol       Date:  2015-06-27       Impact factor: 2.490

3.  Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015.

Authors:  Robert A Kyle; Dirk R Larson; Paul J Kurtin; Shaji Kumar; James R Cerhan; Terry M Therneau; S Vincent Rajkumar; Celine M Vachon; Angela Dispenzieri
Journal:  Mayo Clin Proc       Date:  2019-01-31       Impact factor: 7.616

Review 4.  Approach to the Diagnosis of Amyloidosis.

Authors:  Richa Juneja; H P Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-09       Impact factor: 0.900

5.  Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.

Authors:  Rondell P Graham; Luigi M Terracciano; Alexander Meves; Patrick M Vanderboom; Surendra Dasari; Matthew M Yeh; Michael S Torbenson; Michael W Cruise
Journal:  Mod Pathol       Date:  2016-03-25       Impact factor: 7.842

6.  Detection of Amyloid Beta (Aβ) Oligomeric Composition Using Matrix-Assisted Laser Desorption Ionization Mass Spectrometry (MALDI MS).

Authors:  Jasmine S-H Wang; Shawn N Whitehead; Ken K-C Yeung
Journal:  J Am Soc Mass Spectrom       Date:  2018-02-20       Impact factor: 3.109

7.  Disrupting the DREAM transcriptional repressor complex induces apolipoprotein overexpression and systemic amyloidosis in mice.

Authors:  Pirunthan Perampalam; Haider M Hassan; Grace E Lilly; Daniel T Passos; Joseph Torchia; Patti K Kiser; Andrea Bozovic; Vathany Kulasingam; Frederick A Dick
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

8.  DnaJ Heat Shock Protein Family B Member 9 Is a Novel Biomarker for Fibrillary GN.

Authors:  Surendra Dasari; Mariam P Alexander; Julie A Vrana; Jason D Theis; John R Mills; Vivian Negron; Sanjeev Sethi; Angela Dispenzieri; W Edward Highsmith; Samih H Nasr; Paul J Kurtin
Journal:  J Am Soc Nephrol       Date:  2017-11-02       Impact factor: 10.121

9.  Analysis of Amyloid in Medullary Thyroid Carcinoma by Mass Spectrometry-Based Proteomic Analysis.

Authors:  Lori A Erickson; Julie A Vrana; Jason Theis; Michael Rivera; Ricardo V Lloyd; Ellen McPhail; Jun Zhang
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

10.  Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII.

Authors:  Samih H Nasr; Surendra Dasari; Linda Hasadsri; Jason D Theis; Julie A Vrana; Morie A Gertz; Prasuna Muppa; Michael T Zimmermann; Karen L Grogg; Angela Dispenzieri; Sanjeev Sethi; W Edward Highsmith; Giampaolo Merlini; Nelson Leung; Paul J Kurtin
Journal:  J Am Soc Nephrol       Date:  2016-06-13       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.